Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity

Journal of Clinical Oncology

Volumn 24, Issue 13, 2006, Pages 2105-2112

  Strauss, Sandra J ^a   Maharaj, Lenushka ^a   Hoare, Susan ^a   Johnson, Peter W ^a   Radford, John A ^a   Vinnecombe, Sarah ^a   Millard, Lynda ^a   Rohatiner, Ama ^a   Boral, Anthony ^a   Trehu, Elizabeth ^a   Schenkein, David ^a   Balkwill, Frances ^a   Joel, Simon P ^a   Lister, T Andrew ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BORTEZOMIB; DOXORUBICIN; INTERLEUKIN 6; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CYTOKINE; PYRAZINE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; B CELL LYMPHOMA; CANCER FATIGUE; CANCER RELAPSE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE ACTIVITY; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; HYPOTENSION; IN VITRO STUDY; INFECTION; LYMPHOBLASTOMA; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHIC PAIN; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; T CELL LEUKEMIA; THROMBOCYTOPENIA; TRANSAMINITIS; VOMITING; AGED; BLOOD; CELL SURVIVAL; IMMUNOLOGY; LYMPHOMA; MIDDLE AGED; RECURRENT DISEASE; TUMOR CELL LINE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; CELL SURVIVAL; CYTOKINES; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PYRAZINES; RECURRENCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646462752     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.6789     Document Type: Article

References (34)

1. Clarke CA, Glaser SL: Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 94:2015-2023, 2002
2. Fisher RI, Gaynor ER, Dahlberg S, et al: A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 5:91-95, 1994 (suppl 2)
3. Johnson PW, Rohatiner AZ, Whelan JS, et al: Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol 13:140-147, 1995
4. Fisher RI, Dahlberg S, Nathwani BN, et al: A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories) - A Southwest Oncology Group study. Blood 85:1075-1082, 1995
5. Norton AJ, Matthews J, Pappa V, et al: Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 6:249-256, 1995
6. Hiscott J, Kwon H, Genin P: Hostile takeovers: Viral appropriation of the NF-kappaB pathway. J Clin Invest 107:143-151, 2001
7. Schwartz SA, Hernandez A, Mark Evers B: The role of NF-kappaB/IkappaB proteins in cancer: Implications for novel treatment strategies. Surg Oncol 8:143-153, 1999
8. Turco MC, Romano MF, Petrella A, et al: NF-kappaB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia 18:11-17, 2004
9. Emmerich F, Meiser M, Hummel M, et al: Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 94:3129-3134, 1999
10. Pham LV, Tamayo AT, Yoshimura LC, et al: Inhibition of constitutive NF-kappaB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171:88-95, 2003
11. Heckman CA, Mehew JW, Boxer LM: NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 21:3898-3908, 2002
12. Davis RE, Brown KD, Siebenlist U, et al: Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194:1861-1874, 2001
13. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076, 2001
14. Zheng B, Georgakis GV, Li Y, et al: Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 10:3207-3215, 2004
15. Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622, 1999
16. LeBlanc R, Catley LP, Hideshima T, et al: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62:4996-5000, 2002
17. Mitsiades N, Mitsiades CS, Poulaki V, et al: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 99:14374-14379, 2002
18. Ling YH, Liebes L, Jiang JD, et al: Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9:1145-1154, 2003
19. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427, 2002
20. O'Connor OA, Wright J, Moskowitz C, et al: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-684, 2005
21. Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-675, 2005
22. Weber D, Treon SP, Emmanouilides C, et al: Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:127-131, 2003
23. Cheson BD, Horning SJ, Coiffier B, et al: Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 17:1244-1253, 1999
24. Johnson PW, Watt SM, Betts DR, et al: Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/ stromal cell system. Blood 82:1848-1857, 1993
25. Holford NH, Sheiner LB: Kinetics of pharmacologic response. Pharmacol Ther 16:143-166, 1982
26. O'Connor O, Wright J, Moskowitz C, et al: Targeting the proteasome pathway with bortezomib in patients with mantle cell (MCL) and follicular lymphoma (FL) produces prolonged progression free survival among responding patients: Results of a multicentre phase II experience. Ann Oncol 16:99, 2005 (abstr)
27. Belch A, Kouroukis T, Crump M, et al: Phase II trial of bortezomib in mantle cell lymphoma. Blood 104:608, 2004 (suppl V)
28. Treon SP, Hunter Z, Matous J, et al: Phase II study of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Interim results of WMCTG 03-248. Ann Oncol 16:098, 2005 (suppl V)
29. Younes A, Pro B, Romaguera J, et al: Safety and efficacy of bortezomib (Velcade) for the treatment of relapsed classical Hodgkin's disease. Blood 104:2638, 2004 (abstr)
30. Oltersdorf T, Elmore SW, Shoemaker AR, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681, 2005
31. Chen C, White D, Kouroukis C, et al: Antitumor activity of bortezomib (PS-341; Velcade) in a phase II study of patients with previously untreated or treated Waldenstrom's macroglobulinemia (WM). Blood 104:3278, 2004 (abstr)
32. Masdehors P, Omura S, Merle-Beral H, et al: Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 105:752-757, 1999
33. Warzocha K, Salles G, Bienvenu J, et al: Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol 15:499-508, 1997
34. Zinzani PL, Baccini C, Zaccaria A, et al: Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma. Eur J Haematol 57:335-340, 1996